D and Ds hadronic branching fractions at B factories

Recent measurements of hadronic branching fractions of D and Ds mesons, performed by the BaBar and Belle experiments at the asymmetric e+e- B factories colliders PEP II and KEKB, are reviewed.Comment: To be published in the proceedings of CHARM07, Ithaca, NY, August 2007, eConf C07080

Estimation of distribution parameters as a tool for model-based system engineering and model identification

The estimation of the parameters of a probability distribution (e.g., moments) plays an important role both in the model-based system engineering (e.g., analysis and verification through Statistical Model Checking (SMC)) and in the identification of parameters of predictive models (e.g., systems biology, social networks). The contribution of this PhD thesis is both on the algorithm side and on the modeling side. On the algorithm side, we overview a set of Monte Carlo-based Statistical Model Checking tools and algorithms for the verification of Cyber-Physical Systems, and we provide selection criteria for the verification problem at hand. Furthermore, we present an efficient Monte Carlo-based algorithm to estimate the expected value of a multivariate random variable, when marginal density functions are not known. We prove the correctness of our algorithm, we give an Upper Bound and a Lower Bound to its complexity and we present experimental results confirming our evaluations. On the modeling side, we present a mechanistic and identifiable model to predict, at the node level and at a set of nodes level, the expected value of the retweeting rate of a message inside a social network, at a certain time. Our model parameters are random variables, whose distribution parameters are estimated from an available dataset. We experimentally show that our model reliably predicts both the qualitative and the quantitative time behavior of retweeting rates. This is confirmed by the high correlation between the predicted and the observed data. These results enable a simulation-based analysis of users or of a set of users' behaviors inside a network

Charmed meson decays: Theoretical overview and experimental results

The study of the charmed meson decays is getting a renewable interest because it provides a critical input to the CKM-γ measurements. In addition the discovery of new physics can be revealed in the search for the mixing and CP violation and the large coupling to the light mesons makes charm decays an important probe of light meson spectroscopy. The Dalitz plot technique and a selection of recent experimental results are briefly reviewed

Validation of the Clinical COPD questionnaire in Italian language

BACKGROUND: The development and validation study of the Clinical Chronic Obstructive Disease (COPD) Questionnaire (CCQ) has recently been published in this journal. The CCQ is the first questionnaire that incorporates both clinician and patient guideline goals in the clinical control evaluation of patients with COPD in general clinical practice. The aim of this study is the validation of the CCQ questionnaire in Italian, in specific pulmonary disease clinical practice. METHODS: Validity was tested on a population of healthy subjects and patients with COPD, using the Italian validated version of the Short Form Health Survey (SF-36) and guideline recommended routine measurement in COPD patients (FEV(1), FVC, BMI and functional dyspnoea). Test-retest reliability was tested by re-administering the CCQ after 2 weeks. Responsiveness was tested by re-administering the CCQ after three weeks of hospital pulmonary rehabilitation. Distance walked and Borg breathlessness rating were measured at the end of the six-minute walking test (6 MWT), before and after rehabilitation. RESULTS: Cross-sectional data were collected from 175 subjects (55 healthy; 40 mild-moderate, 50 severe and 25 very severe COPD). Cronbach's alpha was high (0.89). The CCQ scores in patients were significantly worse than in healthy subjects. The CCQ total score in patients with COPD was significantly worse in those with BMI < = 21. Significant correlations were found between the CCQ total score and domains of the SF-36 (rho = -0.43 to rho = -0.72). The correlation between the CCQ and FEV1 % predicted was rho = -0.57. The correlation between the CCQ and MRC was rho = 0.63. Test-retest reliability was determined in 112 subjects over a period of two weeks (Intra Class Coefficient = 0.99). Forty-six patients with COPD showed significant improvement in CCQ scores, distance-walked and Borg breathlessness rating after 3 weeks of pulmonary rehabilitation, indicating CCQ responsiveness. CONCLUSIONS: The CCQ is self-administered and has been specially developed to measure clinical control in patients with COPD. Data support its validity, reliability and responsiveness in Italian and in specific pulmonary disease clinical practice

Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach

Background: in advanced ovarian cancer, over the last 10 years no studies have demonstrated more appropriate therapeutic options compared to the current standard Carboplatin-Paclitaxel (Cb-P) regimen. Two phase III randomized studies (GOG-218 36 and ICON-7 37) have recently demonstrated the efficacy of bevacizumab (recombinant monoclonal antibody that binds with a high affinity to VEGF-A) in adjunct to Cb-P, with 12-15 months maintenance treatment. Methods: the quality of evidence provided was assessed by the use of the GRADE method. Each outcome (deemed to be essential for the purpose of evaluation of the intervention) was assessed to express the degree of confidence in the entity of the beneficial and/or harmful effects of the intervention. Thus, limitations in the quality of conducting the studies (risk of bias), direct applicability/relevance of results to the target population, and precision of results were taken into account. Results: the GOG-218 and the ICON7 study (high-risk subgroup) demonstrated with MODERATE confidence an improvement in critical outcomes PFS and OS, with an absolute reduction of 96 (GOG-218) – 103 (ICON-7) episodes of progression, and 40 (GOG-218) – 135 (ICON-7) deaths per 1 000 patients. A marked increase in risk of hypertension of Grade ≥3 was observed, with an absolute increase of 59 episodes per 1 000 patients in the ICON-7 study, and 157 episodes in the GOG-218 study, respectively, the majority of which were controlled by means of appropriate treatment. The increased risk of other adverse events considered was negligible. Conclusions: the positive effects produced should be viewed as taking prevalence over the negative effects (FAVOURABLE benefit/harm ratio)

Revisiting the mortality of France and Italy with the multiple-cause-of-death approach

In this paper, we use the multiple cause-of-death approach to compare the mortality profiles of France and Italy in 2003. Our analysis leads to a substantial re-evaluation of the role played by certain conditions in the process leading to death. Regarding the associations of causes, we distinguish three patterns that are common to both countries. The numerous similarities that emerge from the comparison of the two countries are a clear indication that, contrary to what is generally thought, misreporting by the certifying physicians generally do not distort the observation.cause of death, France, international comparisons, Italy, mortality, multiple causes of death

adding pertuzumab to adjuvant therapy for high risk her2 positive early breast cancer in aphinity a grade analysis

Aim: Adding pertuzumab to standard trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (IDFS) in the APHINITY trial. However, the magnitude of benefit was marginal in the overall population. Methods: We used GRADE (Grading of Recommendations Assessment, Development and Evaluation) analysis on data from APHINITY to build summary-of-findings tables to evaluate the efficacy, safety and quality of evidence of predefined clinical outcomes for the addition of pertuzumab to trastuzumab-based adjuvant therapy in patients with high-risk HER2-positive early breast cancer. Results: Pertuzumab significantly improved 3-year, event-free, absolute benefit in disease-free survival, IDFS and distant relapse-free interval (DFRI) in patients with node-positive or hormone receptor-negative disease. The analysis provides strength of evidence supporting the addition of pertuzumab in this patient population